The main reasons for implementing the BIC project were: lack of sufficient experience in placing biomarkers products on the market and the need of enhancement of level of diagnostics & personalized health care in the Baltic Sea Region and beyond. Project was started in September 2017 and will end in September 2020. The total budget of Biomarker Commercialization project is EUR 2.55 million. The project is realized under Interreg Baltic Sea Region programme.
The BIC project is aimed to develop a number of tools and results facilitating the commercialization of biomarker products i.e.: from the selection system of most innovative/commercial biomarkers, through set of the tools which encompass technical, business and legal aspects of commercialization, to best & pitfall practices collection based on case studies and successful commercialization.
Currently, the 6-months testing period of the set of main tools has started. After pilots will finished, the tools will be improved by the gained data and facilitated in the final form. What is planned next is dissemination and implementation of the tools into IVDs commercialization mechanism in Baltic Sea Region and beyond.
The BIC consortium invites to participate in validation process of the commercialization tools dedicated to IVD products. Testing and further improvements of the tools are extremely important in the case of incorporation those into “golden standard” of IVDs commercialization. In the broader perspective the invitation also encompasses the initiative of building the strong IVDs environment/network across Baltic Sea Region and beyond, which will contribute to development of personalized medicine and its availability.
The cooperation opportunities within testing of the tools consists of 3 pathways:
1) testing of Screening & Selection tool for choosing of most innovative/commercial biomarkers (target groups: TTOs, business developers, business approached scientists);
2) join to testing of the set of the tools (covering technical, business and legal aspects) for which pilot action has already started (target groups: researchers, SMEs; the BIC consortium triggered 16 pilot sites, the testing will be available if BIC consortium will grant permission);
3) using/access to improved commercialization tools at the spring 2020.
Benefits of testing BIC tools are:
• an access to structured knowledge in the field of biomarker commercialization, from biomarker identification to placing on the market in the form of a diagnostic test;
• an access to an international contact network related to the field of biomarkers and IVDs;
• a contribution to the development of an effective IVD biomarker products commercialization tool;
• a benefit from the increased recognition of a given biomarker project due to participation in an international project;
• a niche competence of optimization of commercialization of biomarker-based diagnostic tests on a Baltic Sea Region and beyond.
To get involved or for more information about project please contact:
1) Katarzyna Piwowarczyk: email@example.com, tel. +48 71 798 58 75
2) Paweł Myszczyński: firstname.lastname@example.org, tel. +48 71 798 58 08
Wrocław Technology Park
Since 2013 at Research Department of Wroclaw Technology Park. Microbiologist, biotechnologist, apart from research work she is responsible for managing and coordinating activities connected with NUTRIBIOMED cluster, stimulating the cooperation between R&D and industry. She is responsible for managing and realization of project, also B+R. Currently she is managing international project called Biomarker Commercialization (Interreg BSR) which aims to develop a number of tools facilitating the commercialization of IVD biomarker products.